Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
95061 trials found · Page 151 of 4754
-
New combo therapy aims to starve liver tumors more effectively
Disease control Recruiting nowTrans-arterial chemoembolization (TACE) is the most commonly used therapy for patients with unresectable hepatocellular carcinoma (HCC). TACE is a minimally invasive procedure that involves placing a catheter into the artery in the liver that feeds the tumor, administering chemot…
Phase: PHASE1, PHASE2 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Engineered immune cells take on Hard-to-Treat solid tumors
Disease control Not yet recruitingThis Phase 1, open-label, non-randomized study will enroll adult subjects with relapsed or refractory non-central nervous system (CNS) malignant solid tumors expressing glypican-3 (GPC3) to examine the safety, feasibility, and efficacy of administering T cell products derived fro…
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
New app aims to tame anger in veterans with brain injury and PTSD
Symptom relief Not yet recruitingThis randomized clinical trial will enroll 100 Veteran-family/friend dyads to test the efficacy of CALM in treating anger in TBI and PTSD. The investigators hypothesize that compared to an active control group, Veterans randomized to the CALM group will demonstrate: * Significan…
Phase: NA • Sponsor: Duke University • Aim: Symptom relief
Last updated Apr 29, 2026 15:01 UTC
-
New hope for aggressive brain tumors: drug combo shows promise before surgery
Disease control Recruiting nowThis phase II trial compares the effect of GI-102 alone and in combination with pembrolizumab given before surgery in treating patients with IDH wildtype glioblastoma and IDH mutated grade 4 astrocytoma that has come back after a period of improvement (recurrent) or that is growi…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New hope for stubborn lung cancer: drug duo targets STK11 mutation
Disease control Recruiting nowThis phase II trial tests how well GT103 in combination with pembrolizumab works in treating patients with STK11 mutant non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has s…
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 06, 2026 16:03 UTC
-
Nurses take the lead: new study aims to bring HIV prevention shots to rural communities
Prevention Not yet recruitingProject SPEED (Streamlined Protocol for Early Engagement and Delivery of HIV Prevention) is a pragmatic, cluster randomized implementation study evaluating a nurse-driven model for delivering long-acting injectable cabotegravir (LAI-CAB) for HIV pre-exposure prophylaxis (PrEP) wi…
Phase: NA • Sponsor: KC Care Health Center • Aim: Prevention
Last updated May 11, 2026 20:48 UTC
-
Spinal stimulation may help restore arm movement in quadriplegia
Disease control Not yet recruitingThe goal of this RCT study is to evaluate if combining activity-based therapy (ABT) with transcutaneous spinal cord stimulation (tSCS) can improve recovery of arm and hand movement in people with cervical spinal cord injury (SCI). As secondary aims, the study will also investigat…
Phase: NA • Sponsor: Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal • Aim: Disease control
Last updated May 11, 2026 20:53 UTC
-
Ovarian cancer trial uses KELIM score to decide best time for surgery
Disease control Not yet recruitingA prospective, international, multi-center, interventional trial of advanced epithelial ovarian cancer patients offered three cycles of neoadjuvant chemotherapy (NACT) and triaged with KELIM score. Patients with favorable score will undergo interval debulking surgery (IDS) follow…
Phase: NA • Sponsor: Aristotle University Of Thessaloniki • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Smart insulin system may help kids with new diabetes avoid Long-Term problems
Disease control Not yet recruitingThe purpose of this study is to investigate the effect of early initiated automated insulin de-livery (AID) treatment in type diabetes in children aged 7-16 years to glycemic control, diabe-tes distress of patients and caregivers, long-term micro- and macrovascular complications …
Phase: NA • Sponsor: Helsinki University Central Hospital • Aim: Disease control
Last updated May 07, 2026 18:43 UTC
-
New hope for pancreatic cancer: targeted drug combo enters phase 3 trial
Disease control Recruiting nowThis phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil \[5-FU\] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus standard chemotherapy alone in treating pa…
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 16, 2026 07:49 UTC
-
AI could predict your next heart attack months in advance
Diagnosis Not yet recruitingAcute myocardial infarction (AMI) remains a leading cause of mortality worldwide. Although early revascularization has markedly improved short-term outcomes, the incidence of major adverse cardiovascular events after the index event remains unacceptably high, posing a formidable …
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Diagnosis
Last updated May 13, 2026 15:59 UTC
-
New combo therapy aims to jumpstart failing hearts without transplant
Disease control Not yet recruitingThe study will evaluate the impact of a combined device-drug strategy with Impella 5.5 with best practices and optimized GDMT on heart recovery outcomes in patients with decompensated heart failure and cardiogenic shock.
Phase: NA • Sponsor: Abiomed Inc. • Aim: Disease control
Last updated May 16, 2026 07:51 UTC
-
Engineered immune cells take on tough leukemia in kids
Disease control Not yet recruitingThis study is designed to evaluate the safety and effectiveness of CART123 cells either alone or when combined with ruxolitinib in pediatric and young adult subjects with relapsed or refractory AML. Subjects will be enrolled into one of two treatment cohorts: subjects who will re…
Phase: PHASE1 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New hope for rare blood vessel disorders: everolimus trial launches
Disease control Not yet recruitingBackground and Objectives Vascular anomalies are a heterogeneous group of disorders classified into vascular tumors and vascular malformations according to the ISSVA classification. Although most follow a benign course, a subset causes serious complications including organ dysfun…
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Freeze, Don't cut: new study tests ice treatment for breast cancer
Disease control Not yet recruitingThe goal of this randomised controlled trial is to compare ipsilateral breast cancer recurrence rates in patients with early-stage breast cancer between patients treated with breast conserving surgery and patient treated with percutaneous cryo-ablation.
Phase: PHASE3 • Sponsor: Franciscus Gasthuis & Vlietland (Hospital) • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New drug cocktail aims to stop cervical cancer from coming back after surgery
Disease control Not yet recruitingThis study is a single-arm, open-label, multicenter, exploratory clinical trial aimed at observing and evaluating the efficacy and safety of camrelizumab combined with famitinib in the adjuvant treatment of cervical cancer patients after surgery.
Phase: NA • Sponsor: Jin LI • Aim: Disease control
Last updated May 16, 2026 07:51 UTC
-
Engineered immune cells aim to tame autoimmune diseases
Disease control Recruiting nowThis is an exploratory, open-label, single-arm Phase 1 clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of QT-219C. QT-219C is a universal allogeneic chimeric antigen receptor T-cell (CAR-T) product targeting both CD19 and BCMA. The study tar…
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated May 08, 2026 12:02 UTC
-
Artificial cornea implant could give sight back to the blind
Disease control Not yet recruitingThis is a prospective, multicenter, randomized controlled (1:1) non-inferiority clinical trial. A total of 54 subjects are scheduled to be enrolled at no fewer than 2 study sites in China. After providing written informed consent, all subjects will undergo screening assessments.…
Phase: NA • Sponsor: Shanghai Vision Science Engineer Medical Equipment Co., Ltd • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New combo therapy targets rare stomach cancer that resists standard treatment
Disease control Not yet recruitingAlpha-fetoprotein-producing gastric cancer (AFP-positive gastric cancer, AFP-GC), a rare and highly aggressive subtype of gastric cancer, accounts for 1.3% to 15% of all gastric cancer cases. Its clinical features are significantly different from those of common gastric cancer. N…
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New triple therapy hopes to outsmart tough esophageal cancer
Disease control Not yet recruitingEsophageal squamous cell carcinoma (ESCC) is a common malignant tumor worldwide, with particularly high incidence in East Asian regions such as China, and is associated with poor patient prognosis. In recent years, immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 antibodies) c…
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 15, 2026 11:55 UTC